Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 3/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 3/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10301901 | 0.96 | SCN9A (0.35) | TUBB1MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL10301900 | 0.90 | TUBB1 (0.40) | TUBB1 | |
| SCHEMBL12739060 | 0.87 | THRA (0.37) | THRATHRBTUBB1MAPTALDH1A1 | |
| SCHEMBL12739063 | 0.87 | THRA (0.37) | THRATHRBTUBB1MAPTALDH1A1 | |
| SCHEMBL12739062 | 0.87 | THRA (0.37) | THRATHRBTUBB1MAPTALDH1A1 | |
| SCHEMBL15495057 | 0.87 | TUBB1 (0.40) | THRATHRBTUBB1MAPTALDH1A1 | |
| SCHEMBL10301907 | 0.86 | TUBB1 (0.33) | TUBB1 | |
| SCHEMBL10301904 | 0.86 | THRA (0.32) | THRATHRBTUBB1MAPTALDH1A1 | |
| SCHEMBL10301905 | 0.86 | THRA (0.32) | THRATHRBTUBB1MAPTALDH1A1 | |
| SCHEMBL12739055 | 0.86 | SMN1; SMN2 (0.36) | THRATHRBTUBB1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | THRA 2022/4885THRB 3016/4885TUBB1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.